### Table I-5

**AGE-ADJUSTED SEER INCIDENCE AND U.S. DEATH RATES AND 5-YEAR RELATIVE SURVIVAL RATES**

By Primary Cancer Site, Sex and Time Period

#### Whites

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Male</td>
<td>Female</td>
<td>Male</td>
</tr>
<tr>
<td>All Sites</td>
<td>478.4</td>
<td>558.3</td>
<td>424.6</td>
</tr>
<tr>
<td>Oral Cavity &amp; Pharynx:</td>
<td>10.5</td>
<td>15.7</td>
<td>6.1</td>
</tr>
<tr>
<td>Lip</td>
<td>1.0</td>
<td>1.7</td>
<td>0.4</td>
</tr>
<tr>
<td>Tongue</td>
<td>2.8</td>
<td>4.2</td>
<td>1.6</td>
</tr>
<tr>
<td>Salivary gland</td>
<td>1.2</td>
<td>1.7</td>
<td>0.9</td>
</tr>
<tr>
<td>Floor of mouth</td>
<td>0.7</td>
<td>1.1</td>
<td>0.4</td>
</tr>
<tr>
<td>Gum &amp; other oral cavity</td>
<td>1.6</td>
<td>1.9</td>
<td>1.3</td>
</tr>
<tr>
<td>Nasopharynx</td>
<td>0.4</td>
<td>0.6</td>
<td>0.2</td>
</tr>
<tr>
<td>Tonsil</td>
<td>1.5</td>
<td>2.5</td>
<td>0.6</td>
</tr>
<tr>
<td>Oropharynx</td>
<td>0.3</td>
<td>0.5</td>
<td>0.2</td>
</tr>
<tr>
<td>Hypopharynx</td>
<td>0.7</td>
<td>1.2</td>
<td>0.3</td>
</tr>
<tr>
<td>Other oral cavity &amp; pharynx</td>
<td>0.3</td>
<td>0.4</td>
<td>0.1</td>
</tr>
<tr>
<td>Digestive System:</td>
<td>87.4</td>
<td>107.1</td>
<td>71.8</td>
</tr>
<tr>
<td>Esophagus</td>
<td>4.7</td>
<td>7.8</td>
<td>4.9</td>
</tr>
<tr>
<td>Stomach</td>
<td>7.1</td>
<td>10.2</td>
<td>4.7</td>
</tr>
<tr>
<td>Small intestine</td>
<td>1.7</td>
<td>2.0</td>
<td>1.4</td>
</tr>
<tr>
<td>Colon &amp; Rectum:</td>
<td>52.0</td>
<td>61.4</td>
<td>44.7</td>
</tr>
<tr>
<td>Colon</td>
<td>37.6</td>
<td>42.7</td>
<td>33.6</td>
</tr>
<tr>
<td>Rectum</td>
<td>14.5</td>
<td>18.6</td>
<td>11.1</td>
</tr>
<tr>
<td>Anus, anal canal &amp; anorectum</td>
<td>1.5</td>
<td>1.3</td>
<td>1.7</td>
</tr>
<tr>
<td>Liver &amp; Intrahep</td>
<td>5.1</td>
<td>7.8</td>
<td>2.8</td>
</tr>
<tr>
<td>Liver</td>
<td>4.5</td>
<td>7.0</td>
<td>2.4</td>
</tr>
<tr>
<td>Intrahep bile duct</td>
<td>0.6</td>
<td>0.7</td>
<td>0.2</td>
</tr>
<tr>
<td>Gallbladder</td>
<td>1.1</td>
<td>0.8</td>
<td>1.4</td>
</tr>
<tr>
<td>Other biliary</td>
<td>1.6</td>
<td>2.0</td>
<td>1.3</td>
</tr>
<tr>
<td>Pancreas</td>
<td>11.1</td>
<td>12.7</td>
<td>9.8</td>
</tr>
<tr>
<td>Retropertitoneum</td>
<td>0.4</td>
<td>0.5</td>
<td>0.4</td>
</tr>
<tr>
<td>Peritoneum, omentum &amp; mesentery</td>
<td>0.7</td>
<td>0.1</td>
<td>1.1</td>
</tr>
<tr>
<td>Other digestive system</td>
<td>0.5</td>
<td>0.5</td>
<td>0.4</td>
</tr>
<tr>
<td>Respiratory System</td>
<td>70.6</td>
<td>89.5</td>
<td>56.7</td>
</tr>
<tr>
<td>Nose, nasal cavity &amp; middle ear</td>
<td>0.7</td>
<td>0.9</td>
<td>0.5</td>
</tr>
<tr>
<td>Larynx</td>
<td>3.7</td>
<td>6.6</td>
<td>1.4</td>
</tr>
<tr>
<td>Lung &amp; bronchus</td>
<td>66.0</td>
<td>81.7</td>
<td>54.7</td>
</tr>
<tr>
<td>Pleura&lt;sup&gt;d&lt;/sup&gt;</td>
<td>0.0</td>
<td>0.1</td>
<td>0.0</td>
</tr>
<tr>
<td>Trachea &amp; other respiratory organs</td>
<td>0.2</td>
<td>0.3</td>
<td>0.1</td>
</tr>
<tr>
<td>Bones &amp; joints</td>
<td>0.9</td>
<td>1.1</td>
<td>0.8</td>
</tr>
<tr>
<td>Soft tissue (incl heart)</td>
<td>3.1</td>
<td>3.7</td>
<td>2.6</td>
</tr>
<tr>
<td>Skin (ex basal &amp; squam):</td>
<td>22.9</td>
<td>29.0</td>
<td>18.6</td>
</tr>
<tr>
<td>Melanoma of the skin</td>
<td>21.1</td>
<td>26.5</td>
<td>17.3</td>
</tr>
<tr>
<td>Other non-epithelial skin</td>
<td>1.8</td>
<td>2.5</td>
<td>1.4</td>
</tr>
<tr>
<td>Breast</td>
<td>72.4</td>
<td>12.4</td>
<td>130.0</td>
</tr>
<tr>
<td>Breast (in situ)</td>
<td>16.0</td>
<td>0.2</td>
<td>30.1</td>
</tr>
</tbody>
</table>

**Note:** Incidence and death rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

<sup>a</sup> SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose–Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SUM/LA, Kentucky, Louisiana and New Jersey).

<sup>b</sup> NCHS public use data file for the total US.

<sup>c</sup> SEER 17 areas. California excluding SF/SUM/LA, Kentucky, Louisiana, and New Jersey contribute cases for diagnosis years 2000-2002. The remaining 13 SEER Areas contribute cases for the entire period 1996-2002.

<sup>d</sup> Mesotheliomas of the Pleura are included in the separate group Mesothelioma for incidence but are included in the Pleura grouping for mortality.

- Statistical could not be calculated due to less than 16 cases in the time interval.
### Table I-5 - continued

#### AGE-ADJUSTED SEER INCIDENCE AND U.S. DEATH RATES AND 5-YEAR RELATIVE SURVIVAL RATES

By Primary Cancer Site, Sex and Time Period

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Total</td>
<td>Males</td>
<td>Females</td>
</tr>
<tr>
<td><strong>Female Genital System:</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cervix uteri</td>
<td>27.3</td>
<td>51.0</td>
<td>9.2</td>
</tr>
<tr>
<td>Corpus uteri</td>
<td>12.8</td>
<td>23.8</td>
<td>1.1</td>
</tr>
<tr>
<td>Uterus, NOS</td>
<td>0.3</td>
<td>0.5</td>
<td>1.2</td>
</tr>
<tr>
<td>Ovary d</td>
<td>7.8</td>
<td>14.5</td>
<td>5.2</td>
</tr>
<tr>
<td>Vagina</td>
<td>0.4</td>
<td>0.7</td>
<td>0.1</td>
</tr>
<tr>
<td>Vulva</td>
<td>1.3</td>
<td>2.3</td>
<td>0.3</td>
</tr>
<tr>
<td>Other female</td>
<td>0.4</td>
<td>0.7</td>
<td>0.1</td>
</tr>
<tr>
<td><strong>Male Genital System:</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Urinary System</td>
<td>76.0</td>
<td>170.8</td>
<td>14.4</td>
</tr>
<tr>
<td>Urinary bladder</td>
<td>36.6</td>
<td>59.5</td>
<td>19.4</td>
</tr>
<tr>
<td>Kidney &amp; renal pelvis</td>
<td>22.8</td>
<td>40.2</td>
<td>10.0</td>
</tr>
<tr>
<td>Ureter</td>
<td>13.0</td>
<td>18.0</td>
<td>9.0</td>
</tr>
<tr>
<td>Other urinary system</td>
<td>0.6</td>
<td>0.8</td>
<td>0.4</td>
</tr>
<tr>
<td><strong>Endocrine System:</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Thyroid</td>
<td>9.2</td>
<td>52.2</td>
<td>13.2</td>
</tr>
<tr>
<td>Other endocrine &amp; thymus</td>
<td>8.6</td>
<td>4.5</td>
<td>12.7</td>
</tr>
<tr>
<td><strong>Lymphoma:</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hodgkin lymphoma</td>
<td>22.8</td>
<td>27.1</td>
<td>19.3</td>
</tr>
<tr>
<td>Non-Hodgkin lymphoma</td>
<td>2.9</td>
<td>3.2</td>
<td>2.6</td>
</tr>
<tr>
<td><strong>Myeloma:</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Leukemia:</td>
<td>12.7</td>
<td>16.5</td>
<td>9.8</td>
</tr>
<tr>
<td>Lymphocytic:</td>
<td>6.1</td>
<td>8.2</td>
<td>4.5</td>
</tr>
<tr>
<td>Acute lymphocytic</td>
<td>1.7</td>
<td>1.9</td>
<td>1.5</td>
</tr>
<tr>
<td>Chronic lymphocytic</td>
<td>4.0</td>
<td>5.6</td>
<td>2.8</td>
</tr>
<tr>
<td><strong>Myeloid &amp; Monocytic:</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acute myeloid</td>
<td>5.8</td>
<td>7.3</td>
<td>4.7</td>
</tr>
<tr>
<td>Chronic myeloid</td>
<td>3.8</td>
<td>4.7</td>
<td>3.1</td>
</tr>
<tr>
<td>Acute monocytic</td>
<td>1.5</td>
<td>2.0</td>
<td>1.2</td>
</tr>
<tr>
<td><strong>Other:</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acute other</td>
<td>0.3</td>
<td>0.4</td>
<td>0.3</td>
</tr>
<tr>
<td>Acute lymphoid</td>
<td>0.2</td>
<td>0.2</td>
<td>0.1</td>
</tr>
<tr>
<td>Monocytic</td>
<td>0.5</td>
<td>0.7</td>
<td>0.2</td>
</tr>
<tr>
<td>Non-Hodgkin lymphoma</td>
<td>22.8</td>
<td>27.1</td>
<td>19.3</td>
</tr>
<tr>
<td><strong>Myeloma:</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Leukemia:</td>
<td>12.7</td>
<td>16.5</td>
<td>9.8</td>
</tr>
<tr>
<td>Lymphocytic:</td>
<td>6.1</td>
<td>8.2</td>
<td>4.5</td>
</tr>
<tr>
<td>Acute lymphocytic</td>
<td>1.7</td>
<td>1.9</td>
<td>1.5</td>
</tr>
<tr>
<td>Chronic lymphocytic</td>
<td>4.0</td>
<td>5.6</td>
<td>2.8</td>
</tr>
<tr>
<td><strong>Other:</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other acute</td>
<td>0.8</td>
<td>1.0</td>
<td>0.6</td>
</tr>
<tr>
<td><strong>Kaposi Sarcoma:</strong> f</td>
<td>0.6</td>
<td>1.1</td>
<td>0.1</td>
</tr>
<tr>
<td><strong>Mesotheiloma:</strong> f</td>
<td>1.2</td>
<td>2.3</td>
<td>0.5</td>
</tr>
<tr>
<td><strong>Ill-defined &amp; unspecified:</strong></td>
<td>11.0</td>
<td>12.6</td>
<td>9.8</td>
</tr>
</tbody>
</table>

Note: Incidence and death rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

a SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey).

b NCHS public use data file for the total US.


d Ovary excludes borderline cases or histologies 8442, 8451, 8462, 8472, and 8473.

e Due to coding changes, Brain & Nervous System mortality are no longer shown separately.

- Rate not shown for mortality. Category did not exist in mortality coding until 1999.

- Statistical could not be calculated due to less than 16 cases in the time interval.